The Most Common Use Case Nobody Studied
Migraine is among the most prevalent disabling conditions on earth, affecting roughly a billion people, and cannabis use among migraineurs is proportionally enormous: surveys consistently find that a large fraction of migraine patients have used cannabis for their attacks, and patient-report studies describe meaningful relief rates that, if they held up in controlled trials, would make cannabis among the most effective acute migraine treatments available. The controlled-trial evidence, however, is among the thinnest for any major use case: a handful of small studies, mostly of synthetic cannabinoids rather than the plant itself, with results that are promising but far from definitive. Migraine is thus the purest case in this series of a use case where the patient experience and the clinical evidence live in different time zones. This post is the honest map: the survey signal, the trial data, the plausible mechanisms, and what a migraine patient can reasonably conclude.
The Survey Signal
The patient-report literature is consistent and striking. Retrospective studies of migraine patients using cannabis describe substantial fractions reporting relief of acute attacks, with some studies finding improvement rates above 50 percent and with many patients reporting cannabis as more effective than their prescription acute treatments. A much-discussed 2019 study of medical-cannabis patients found that over 40 percent reported overall headache frequency reductions with cannabis use, though the design limitations (retrospective, self-selected, uncontrolled) applied in full. The reports share a consistent phenomenology: cannabis taken at attack onset, or preventively in frequent migraineurs, reduces attack intensity and duration, with the acute effect arriving within the relevant window and the preventive effect requiring regular dosing.
The signal is strong enough, and the population large enough, that the professional headache societies have taken formal notice: the American Headache Society and the American Academy of Neurology have published cautious engagement statements acknowledging the patient reports and calling for the rigorous trials the evidence lacks.
The Controlled Evidence
The trial literature is small enough to list. The synthetic THC analogs (nabilone, dronabinol) have been tested in small trials for migraine and cluster headache, with modest positive signals for nabilone in particular (some studies finding it comparable to or better than standard comparators for chronic daily headache and migraine, at small sample sizes and with significant dropout from side effects). Plant-cannabis trials in migraine are essentially absent from the literature, a gap explained by the scheduling barriers and research-funding problems this series has documented everywhere. The National Academies' landmark review rated the evidence for cannabinoids in headache as limited, the second-lowest confidence tier, explicitly noting the reliance on patient reports and small trials.
The honest summary: the evidence supports a plausible, patient-reported benefit that rigorous trials have not yet confirmed or refuted. For a condition where many patients are failed by the available toolkit (the triptans work for perhaps half of attacks, the preventives help a fraction of users, and the new CGRP monoclonals are expensive and imperfect), a modestly evidenced additional option with a manageable risk profile is legitimately worth a structured trial for many patients.
The Mechanisms
The biological plausibility is real and worth describing. The endocannabinoid system modulates the trigeminovascular system, the pain-signaling network whose activation drives migraine, and preclinical work shows cannabinoid effects on the relevant receptors in the trigeminal ganglion. The endocannabinoid system also participates in the modulation of cortical spreading depression, the wave of neuronal depression thought to underlie the migraine aura, and in the regulation of the hypothalamic and brainstem circuits involved in attack generation. The anecdotally reported pattern (effective at onset, less effective once the attack is fully established) matches the mechanism story: the compounds appear to modulate the attack's initiation and propagation more than its fully developed pain.
The overuse-rebound question deserves its own paragraph, because it is the specific trap for this indication: medication-overuse headache is a well-documented phenomenon in which frequent use of acute headache medications (triptans, opioids, and also, plausibly, cannabis) transforms episodic migraine into a chronic daily headache, and the patient-report literature has begun documenting exactly this pattern in heavy daily cannabis-using migraineurs, with withdrawal-triggered headache on cessation described in case series. The harm reduction frame: cannabis for migraine, like every acute treatment, is a tool with a frequency ceiling, and the preventive pattern (regular low-dose use to reduce attack frequency) that many patients report must be weighed against the medication-overuse risk that the daily pattern invites.
The Practical Framework for Patients
The distilled guidance for the migraine patient considering cannabis, in this series' structured-trial format: treat it as a monitored experiment with defined outcomes (attack frequency, attack severity, acute-treatment use), not an open-ended adoption; for acute use, dose at onset in the sub-psychoactive-to-mild range, since the patient reports suggest the effect does not require intoxication and the edibles' onset-timing problem makes inhaled routes the practical acute option; for preventive use, keep the daily-dose discipline of this series' dependence coverage firmly in view, with the medication-overuse ceiling explicitly respected; avoid the combinatorial stacking with alcohol and sedatives that the interaction posts cover; audit against the serotonergic preventive medications (the SSRIs and SNRIs common in migraine comorbidity) via the series' CYP post; and involve the treating neurologist, both for the monitoring structure and because the rest of the migraine toolkit (the CGRP era has genuinely changed the preventive landscape) deserves full deployment before cannabis is asked to carry the load alone.
The Bottom Line
Migraine and cannabis sit in the classic gap of the field: enormous patient-reported benefit, thin controlled evidence, plausible mechanism, and a population large and suffering enough that the missing trials are a genuine scandal of research priorities. The patient reports cannot be dismissed and should not be believed at face value; the truth, as everywhere in this series, is probably conditional, individual, and waiting for the studies that someone should have run a decade ago. In the meantime, the structured-trial discipline, honest monitoring, the overuse ceiling, and the neurologist in the loop give the migraine patient the best available version of an unresolved question, which is more than the marketing offers and less than the patients deserve.
